Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase

Hang-Ping Yao; Xiang-Min Tong; Ming-Hai Wang

doi:10.1016/j.drudis.2020.11.002

Pharmaceutical strategies in the emerging era of antibody-based biotherapeutics for the treatment of cancers overexpressing MET receptor tyrosine kinase

Drug Discov Today. 2021 Jan;26(1):106-121. doi: 10.1016/j.drudis.2020.11.002. Epub 2020 Nov 7.

Authors

Hang-Ping Yao¹, Xiang-Min Tong², Ming-Hai Wang³

Affiliations

¹ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; National Clinical Research Center for Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Electronic address: yaohangping@zju.edu.cn.
² Department of Hematology, Zhejiang Provincial People's Hospital and People's Hospital of Hangzhou Medical College, Hangzhou, China.
³ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; National Clinical Research Center for Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Cancer Biology Research Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA; Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA. Electronic address: minghai.wang@ttuhsc.edu.

PMID: 33171292
DOI: 10.1016/j.drudis.2020.11.002

Abstract

Pharmaceutical innovation in the development of novel antibody-based biotherapeutics with increased therapeutic indexes makes MET-targeted cancer therapy a clinical reality.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antibodies, Bispecific / pharmacology
Antineoplastic Agents, Immunological / pharmacology*
Biopharmaceutics* / methods
Biopharmaceutics* / trends
Drug Discovery
Humans
Immunoconjugates / pharmacology
Neoplasms* / drug therapy
Neoplasms* / immunology
Proto-Oncogene Proteins c-met / immunology*
Therapeutic Index, Drug

Substances

Antibodies, Bispecific
Antineoplastic Agents, Immunological
Immunoconjugates
Proto-Oncogene Proteins c-met